GGrantIndex
← Leaderboards

Robin A Pollini

University Of California, San Diego

$6,774,006
Attributed
$6,984,989
Total exposure
5
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY200723
$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$6,984,989 · 5

By mechanism

R01$5,378,966 · 2
R21$848,072 · 2
K01$757,951 · 1

Top collaborators

Most similar at University Of California, San Diego

Same institution · by research overlap

Others in their field

Top investigators on “Base

Research focus

BasePharmacy FacilityDesignPoliciesPharmaceutical PreparationsNeedle SharingInnovationPharmacistsAids PreventionInjecting Drug UserProgramsTrainingCommunitiesCountryUnited StatesMexicoNatural ExperimentSalesInternationalHealth PersonnelHeroinDrug UsageMexicanEnsure

Grant awards (20)

Identifying Stigma Reduction Targets in the Context of an Appalachian HIV Outbreak$222,960
R21 · FY2023 · DA · contact PI
Identifying Stigma Reduction Targets in the Context of an Appalachian HIV Outbreak$203,145
R21 · FY2022 · DA · contact PI
Pharmacy Naloxone Distribution: Assessing a New Tool to Reduce Overdose Mortality$554,670
R01 · FY2021 · DA · contact PI
Pharmacy Naloxone Distribution: Assessing a New Tool to Reduce Overdose Mortality$524,977
R01 · FY2020 · DA · contact PI
Pharmacy Naloxone Distribution: Assessing a New Tool to Reduce Overdose Mortality$552,322
R01 · FY2018 · DA · contact PI
Pharmacy Naloxone Distribution: Assessing a New Tool to Reduce Overdose Mortality$509,210
R01 · FY2017 · DA · contact PI
Pharmacy Naloxone Distribution: Assessing a New Tool to Reduce Overdose Mortality$64,676
R01 · FY2017 · DA · contact PI
Pharmacy Naloxone Distribution: Assessing a New Tool to Reduce Overdose Mortality$661,745
R01 · FY2016 · DA · contact PI
OTC Syringe Sales to Prevent HIV in Underserved Areas of Inland California$544,878
R01 · FY2016 · DA · contact PI
OTC Syringe Sales to Prevent HIV in Underserved Areas of Inland California$639,465
R01 · FY2015 · DA · contact PI
OTC Syringe Sales to Prevent HIV in Underserved Areas of Inland California$673,124
R01 · FY2014 · DA · contact PI
Characterizing Prescription Drug Use in a Representative Sample of U.S. Drivers$197,222
R21 · FY2014 · DA · contact PI
OTC Syringe Sales to Prevent HIV in Underserved Areas of Inland California$653,899
R01 · FY2013 · DA · contact PI
Characterizing Prescription Drug Use in a Representative Sample of U.S. Drivers$224,745
R21 · FY2013 · DA
Defining the Role of Mexican Pharmacies in HIV Prevention-A Mixed Method Approach$157,446
K01 · FY2011 · DA · contact PI
Defining the Role of Mexican Pharmacies in HIV Prevention-A Mixed Method Approach$124,729
K01 · FY2010 · DA · contact PI
Defining the Role of Mexican Pharmacies in HIV Prevention-A Mixed Method Approach$29,700
K01 · FY2010 · DA · contact PI
Defining the Role of Mexican Pharmacies in HIV Prevention-A Mixed Method Approach$151,505
K01 · FY2009 · DA · contact PI
Defining the Role of Mexican Pharmacies in HIV Prevention-A Mixed Method Approach$148,664
K01 · FY2008 · DA · contact PI
Defining the Role of Mexican Pharmacies in HIV Prevention-A Mixed Method Approach$145,907
K01 · FY2007 · DA · contact PI